Nuvectis Pharma, Inc. (NVCT)
$21.12+4.92%Close
SELLCRISIS · day 4
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $560M
- Beta
- -0.26
- P/E (TTM)
- -15.29
- Short % float
- 14.86%
- Days to cover
- 10.3
- SI change
- +6.8%
- 1W
- -3.65%
- 1M
- -6.09%
- vs SPY 1W
- -4.81%
- vs SPY 1M
- -9.08%
Industry peers
FMP comparable companies · ranked by market cap
- NUVBSELLNuvation Bio Inc.$1.7BCRISISQ 4$5.00+1.01%
- SNDXSELLSyndax Pharmaceuticals, Inc.$1.5BCRISISQ 17$16.99+0.53%
- ORICSELLORIC Pharmaceuticals, Inc.$1.2BBEARQ 3$11.99-0.33%
- JANXBUYJanux Therapeutics, Inc.$1.1BRECOVERYQ 12$18.39-0.59%
- VSTMBUYVerastem, Inc.$736MRECOVERYQ 4$8.38+3.33%
- IMMXSELLImmix Biopharma, Inc.$515MCRISISQ 24$9.46+1.83%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on NVCT?
- LOPJLB’s latest quantitative signal on Nuvectis Pharma, Inc. (NVCT) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is NVCT in?
- Nuvectis Pharma, Inc. (NVCT) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Nuvectis Pharma, Inc. (NVCT) do?
- Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug cand…